Literature DB >> 22528787

Phenytoin reduces 5-aminolevulinic acid-induced protoporphyrin IX accumulation in malignant glioma cells.

Martin Hefti1, Ina Albert, Vera Luginbuehl.   

Abstract

Epileptic seizures are among the presenting clinical signs of malignant glioma patients, frequently necessitating treatment with antiepileptic drugs (AEDs). The efficacy of 5-aminolevulinic acid (5-ALA)-based intraoperative fluorescence-guided surgery and photodynamic therapy (PDT) in glioblastoma multiforme (GBM) patients depends on the specific accumulation and total amount of intracellularly synthesized protoporphyrin IX (PpIX) in tumour cells. In this study, we investigated the effect of the AEDs phenytoin (PHY) and levetiracetam (LEVE) on 5-ALA-induced PpIX accumulation in two glioma cell lines (U373 MG and U-87 MG) and primary GBM cells isolated from a human biopsy. After treatment with PHY and LEVE for three days cells were incubated with 1 mM: 5-ALA for 4 h and PpIX accumulation was determined by fluorescence measurement. We observed a decrease in PpIX synthesis of up to 55 ± 12 % in primary GBM cells after incubation with phenytoin. This reduction was dose-dependent for all tested cell lines and primary GBM cells. LEVE on the other hand did not alter PpIX concentration in GBM cells. PDT was performed in vitro by irradiating the GBM cells with light doses from 0.5 to 10 J cm(-2) at 627 nm after AED and 5-ALA treatment. Although less PpIX accumulated in PHY-treated cells, efficacy of PDT was not affected. We assume that damage to the mitochondrial membrane by PHY inhibits PpIX synthesis in vitro, because we showed mitochondrial dysfunction as a result of reduced mitochondrial membrane potential in PHY-treated cells. No change in glutathione status was observed. To evaluate further the effect of PHY on PpIX fluorescence, and to establish its significance in clinical practice, animal and clinical studies are required, because the results presented here imply PHY may reduce intracellular accumulation of PpIX in patients with high-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528787     DOI: 10.1007/s11060-012-0857-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Modulation of migratory activity and invasiveness of human glioma spheroids following 5-aminolevulinic acid-based photodynamic treatment. Laboratory investigation.

Authors:  Nima Etminan; Corinna Peters; Julian Ficnar; Suzan Anlasik; Erich Bünemann; Philipp J Slotty; Daniel Hänggi; Hans-Jakob Steiger; Rüdiger V Sorg; Walter Stummer
Journal:  J Neurosurg       Date:  2011-04-22       Impact factor: 5.115

2.  An integrated diagnosis and therapeutic system using intra-operative 5-aminolevulinic-acid-induced fluorescence guided robotic laser ablation for precision neurosurgery.

Authors:  Hongen Liao; Masafumi Noguchi; Takashi Maruyama; Yoshihiro Muragaki; Etsuko Kobayashi; Hiroshi Iseki; Ichiro Sakuma
Journal:  Med Image Anal       Date:  2010-11-28       Impact factor: 8.545

Review 3.  5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.

Authors:  Q Peng; T Warloe; K Berg; J Moan; M Kongshaug; K E Giercksky; J M Nesland
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

4.  Brain uptake of phenytoin, phenobarbital, and diazepam.

Authors:  R E Ramsay; E J Hammond; R J Perchalski; B J Wilder
Journal:  Arch Neurol       Date:  1979-09

5.  Effect of prolonged phenytoin administration on rat brain gene expression assessed by DNA microarrays.

Authors:  Veronica Mariotti; Erika Melissari; Shirly Amar; Angela Conte; Robert Haim Belmaker; Galila Agam; Silvia Pellegrini
Journal:  Exp Biol Med (Maywood)       Date:  2010-03

6.  Ceruloplasmin expression and its role in iron transport in C6 cells.

Authors:  Yan Zhong Chang; Zhong Ming Qian; Jin Rong Du; Li Zhu; Youjia Xu; Lian-Zhi Li; Chen-Yuen Wang; Qin Wang; Xiao Hu Ge; Kwok Ping Ho; Lijin Niu; Ya Ke
Journal:  Neurochem Int       Date:  2007-01-20       Impact factor: 3.921

7.  Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells.

Authors:  M Ständer; J Dichgans; M Weller
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

8.  Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study.

Authors:  Arya Nabavi; Holger Thurm; Basilios Zountsas; Thorsten Pietsch; Heinrich Lanfermann; Uwe Pichlmeier; Maximilian Mehdorn
Journal:  Neurosurgery       Date:  2009-12       Impact factor: 4.654

9.  Differences between the concentrations of antiepileptic drugs in normal and pathological human brain.

Authors:  V A Sironi; L Ravagnati; G Ettorre; G P Cabrini; F Marossero
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Aromatic antiepileptic drugs and mitochondrial toxicity: effects on mitochondria isolated from rat liver.

Authors:  N A G Santos; W S G Medina; N M Martins; F E Mingatto; C Curti; A C Santos
Journal:  Toxicol In Vitro       Date:  2008-03-15       Impact factor: 3.500

View more
  11 in total

Review 1.  5ALA in pediatric brain tumors is not routinely beneficial.

Authors:  Jonathan Roth; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2017-03-14       Impact factor: 1.475

2.  Clearance of Damaged Mitochondria Through PINK1 Stabilization by JNK and ERK MAPK Signaling in Chlorpyrifos-Treated Neuroblastoma Cells.

Authors:  Jae Hyeon Park; Juyeon Ko; Yun Sun Park; Jungyun Park; Jungwook Hwang; Hyun Chul Koh
Journal:  Mol Neurobiol       Date:  2016-02-18       Impact factor: 5.590

3.  Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells.

Authors:  Johnathan E Lawrence; Christopher J Steele; Richard A Rovin; Robert J Belton; Robert J Winn
Journal:  J Neurooncol       Date:  2015-12-07       Impact factor: 4.130

4.  The Role of 5-ALA in Low-Grade Gliomas and the Influence of Antiepileptic Drugs on Intraoperative Fluorescence.

Authors:  Sergey A Goryaynov; Georg Widhalm; Maria F Goldberg; Danil Chelushkin; Aldo Spallone; Kosta A Chernyshov; Marina Ryzhova; Galina Pavlova; Alexander Revischin; Ludmila Shishkina; Vadim Jukov; Tatyana Savelieva; Loschenov Victor; Alexander Potapov
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

5.  Multicellular "hotspots" harbor high-grade potential in lower-grade gliomas.

Authors:  Alastair J Kirby; José P Lavrador; Istvan Bodi; Francesco Vergani; Ranjeev Bhangoo; Keyoumars Ashkan; Gerald T Finnerty
Journal:  Neurooncol Adv       Date:  2021-02-08

6.  Impact of fluorescence-guided surgery on the improvement of clinical outcomes in glioblastoma patients.

Authors:  Sung Kwon Kim; Seung Hong Choi; Yong Hwy Kim; Chul-Kee Park
Journal:  Neurooncol Pract       Date:  2014-06-25

7.  5-aminolevulinic acid-guided surgery for focal pediatric brainstem gliomas: A preliminary study.

Authors:  Jason Labuschagne
Journal:  Surg Neurol Int       Date:  2020-10-08

Review 8.  Systematic Review and Meta-Analysis of In Vitro Anti-Human Cancer Experiments Investigating the Use of 5-Aminolevulinic Acid (5-ALA) for Photodynamic Therapy.

Authors:  Yo Shinoda; Daitetsu Kato; Ryosuke Ando; Hikaru Endo; Tsutomu Takahashi; Yayoi Tsuneoka; Yasuyuki Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-07

Review 9.  Analysis of Factors Affecting 5-ALA Fluorescence Intensity in Visualizing Glial Tumor Cells-Literature Review.

Authors:  Marek Mazurek; Dariusz Szczepanek; Anna Orzyłowska; Radosław Rola
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

10.  Correlation of Intraoperative 5-ALA-Induced Fluorescence Intensity and Preoperative 11C-Methionine PET Uptake in Glioma Surgery.

Authors:  Kazuhide Shimizu; Kaoru Tamura; Shoko Hara; Motoki Inaji; Yoji Tanaka; Daisuke Kobayashi; Takashi Sugawara; Hiroaki Wakimoto; Tadashi Nariai; Kenji Ishii; Ichiro Sakuma; Taketoshi Maehara
Journal:  Cancers (Basel)       Date:  2022-03-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.